Pionomed Biogenix Is Reimagining Reconstructive Surgery and Cancer Diagnosis Through Clinician-Led Innovation
Innovation in the field of medicine often starts not in laboratories but in hospital operation theaters where physicians have to deal with the drawbacks of existing medical treatment daily. Pionomed Biogenix, which is a startup in the health care technology industry and was launched in 2023 in Thiruvananthapuram, is one of them. The technologies developed by this company aim at making advanced healthcare more precise and convenient for the patient.
The creation of Pionomed Biogenix is rooted in the extensive clinical and research experience of its founders. The company was established by Cranio-Maxillofacial Surgeons Dr. Adersh G.A., PMS College of Dental Science and Research, and Dr. Shivadhath R.P., along with microbiologist Dr. Suvya Surendran, Sree Gokulam Medical College and Research Foundation. Having encountered the challenges of performing complex reconstructive surgeries firsthand, the founders were driven to develop innovative technologies that improve surgical precision, enhance clinical outcomes, and significantly reduce the physical burden on patients.
This vision crystallized following a pivotal moment in the life of Dr. Adersh. It was when he needed to treat a patient suffering from recurrent ameloblastoma and had to adopt the usual technique of fibular bone grafting for reconstruction which is highly invasive and consists of a number of surgeries. The loss of that patient proved to be a wake-up call which prompted a number of years of research aimed at developing a method which would help to avoid unnecessary pain as well as increase surgical accuracy.
The outcome of all the efforts invested is OsseoCraft, defined by the company as the first clinical Delta 3D Bone Graft Printer in the world. While other approaches involve the use of titanium implants or bone taken from a patient’s body for reconstructive purposes, OsseoCraft provides customized bone grafts using patented bio-compatible material. Every bone graft is specifically tailored for a patient based on his anatomical structure which helps to decrease the operating time, avoid potential complications, and eliminate additional surgery to obtain the necessary bone tissue.
Not limited to reconstruction, however, the team also aimed at diagnosing issues in order to help patients in time. That is why, the company has created OmniPath AI – a clinical reasoning platform which has integrated artificial intelligence with a microscope to provide more precise and fast histopathological diagnosis. As mentioned on the website of Pionomed Biogenix, FDA has approved the platform, and now it has provided more than 1,500 accurate diagnoses in the field helping to diagnose cancers.
The distinguishing feature of the company is its perspective. Every product is created by the people working in the clinical area, and thus it helps to create innovative solutions to practical problems in the field. Such an approach allows to produce devices which will be convenient for physicians and surgeons to use.
Even being founded only in 2023, the startup has achieved many awards and recognitions. Among them there is Charaka Award, Nova 2023 Winner, Kerala State Emerging Startup Award, and other mentions in national press.
In this day and age when the field of medicine is moving towards personalized treatment and digitization, a company such as Pionomed Biogenix shows the way of innovation through empathy. By turning personal clinical experiences into technology that will benefit surgery and diagnostics, this company not only moves forward in terms of scientific advancements but changes the face of patient care.
